Press Room


    Press Release - January 14, 2003

    Pheromone Sciences Appoints Jim Wooder to Board of Directors

    Toronto, Ontario (January 14, 2003) - Pheromone Sciences Corp (TSX-V:PHS), is pleased to announce the appointment of Mr. Jim Wooder, well-known and respected Toronto businessman, to its Board of Directors.

    Mr. Wooder brings a wealth of investment knowledge and business acumen to the Pheromone Sciences' Board of Directors. He is currently Vice President of Helix Investments (Canada) Inc., a North American- based venture capital company with assets of $200 million. Mr. Wooder has held this position since 1993. Prior to this Mr.Wooder spent several years in the Canadian Banking Industry. In addition, Mr. Wooder has held senior management positions with prominent investment and venture capital firms.

    Having participated at the Board of Director level in some 50 companies, Mr Wooder is Chairman of The Hanen Centre, an internationally renowned charity that develops programs to assist teachers and parents in the teaching of children with speech problems.

    "We are extremely pleased that Mr. Wooder has accepted this appointment to our Board. His experience and proven abilities as a manager and investor will be of benefit to us as we enter this crucial phase in our development and growth ", commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp.

    The appointment, which is subject to regulatory approval, is part of an ongoing program to enhance the independent nature of the Board.

    In addition, Mr. Douglas Marett's duties as Chief Scientific Officer are now being carried out on a consulting basis.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News